Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-11-21FDA Approved: MELOXICAM — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for MELOXICAM from Zydus Pharmaceuticals USA Inc., as part of an ANDA, indicating approval of an…
-
FDA approval · 2024-11-21FDA Approved: NABUMETONE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for Nabumetone.
-
FDA approval · 2024-11-21FDA Approved: INDOMETHACIN — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for indomethacin submitted by Chartwell RX, LLC. This action represents an approved supplement t…
-
FDA label_change · 2024-11-21FDA Approved: ETODOLAC — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Etodolac by Zydus Pharmaceuticals USA Inc., resulting in labeling updates for this NSAID.
-
FDA approval · 2024-11-21FDA Approved: MELOXICAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for MELOXICAM (meloxicam) under ANDA077944.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-11-21FDA Approved: DICLOFENAC SODIUM — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for a generic diclofenac sodium product from NorthStar Rx LLC.
-
FDA approval · 2024-11-21FDA Approved: INDOMETHACIN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approves a supplemental application for Indomethacin from Amneal Pharmaceuticals LLC (ANDA 091549), authorizing a supplemental change to…
-
FDA label_change · 2024-11-21FDA Approved: SULINDAC — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental labeling change for sulindac from Actavis Pharma, updating the product labeling under the ANDA. This reflects ad…
-
FDA approval · 2024-11-21FDA Approved: ETODOLAC — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approved a supplemental application for Etodolac submitted by Taro Pharmaceuticals U.S.A., Inc.
-
FDA approval · 2024-11-21FDA Approved: ETODOLAC — Supplemental Application (Apotex Corp.)
FDA approves a supplemental ANDA for etodolac from Apotex Corp.
-
FDA approval · 2024-11-21FDA Approved: CELEBREX — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Celebrex (celecoxib) filed by Viatris Specialty LLC. The approval covers changes requested i…
-
FDA approval · 2024-11-21FDA Approved: MELOXICAM — Supplemental Application (AiPing Pharmaceutical, Inc)
FDA approved a supplemental application for meloxicam from AiPing Pharmaceutical, Inc. The approval pertained to updating the labeling under…
-
FDA approval · 2024-11-21FDA Approved: NABUMETONE — Supplemental Application (Chartwell RX, LLC)
FDA has approved a supplemental application for NABUMETONE submitted by Chartwell RX, LLC. The action updates an existing approved ANDA for …
-
FDA label_change · 2024-11-21FDA Approved: DAYPRO — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental labeling application for DAYPRO (oxaprozin) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2024-11-21FDA Approved: NABUMETONE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for Nabumetone submitted by Actavis Pharma, Inc., representing a regulatory change to the existi…
-
FDA approval · 2024-11-21FDA Approved: MELOXICAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for meloxicam, confirming regulatory clearance for the product.
-
FDA approval · 2024-11-21FDA Approved: MELOXICAM — Supplemental Application (Cipla USA Inc.)
The FDA approved a supplemental application for MELOXICAM from Cipla USA Inc., authorizing changes to an existing meloxicam product under an…
-
FDA approval · 2024-11-21FDA Approved: IBUPROFEN — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for ibuprofen from Actavis Pharma, Inc.
-
CLINICAL_TRIALS research · 2024-11-21Clinical Trial Update: A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis. [NA]
A clinical study is evaluating cannabigerol for efficacy in active rheumatoid arthritis; the trial is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: Supporting Patient Care With Electronic Resources in the United States [NA]
This completed clinical trial studied how electronic resources can support patient care for rheumatoid arthritis in the United States.
-
CLINICAL_TRIALS trial_result · 2024-11-19Clinical Trial Update: Mussels, Inflammation and Rheumatoid Arthritis (MIRA) [NA]
A completed clinical trial update from Göteborg University evaluating the relationship between mussels, inflammation, and rheumatoid arthrit…
-
CLINICAL_TRIALS research · 2024-11-18Clinical Trial Update: The Impact of Glycemic Control on Rheumatoid Arthritis Disease Activity on Diabetic Patients
The trial investigates whether glycemic control affects rheumatoid arthritis disease activity in patients with diabetes and is not yet recru…
-
CLINICAL_TRIALS trial_result · 2024-11-15Clinical Trial Update: To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate [Phase 1, Phase 2]
A completed Phase 1/2 study from UCB Pharma evaluated blood levels and safety of CDP6038 in rheumatoid arthritis patients using methotrexate…
-
CLINICAL_TRIALS research · 2024-11-13Clinical Trial Update: JAK Inhibitor Dose TAPering Strategy Study [Phase 4]
A Phase 4 clinical trial is evaluating a dose tapering strategy for a JAK inhibitor in rheumatoid arthritis, and the study is currently not …
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: Clinical Evaluation of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement (CADENCE)
The CADENCE clinical evaluation of the Integra Cadence Total Ankle System for primary ankle joint replacement is currently suspended.